The EI+PBC regimen improved the DCR, ORR, 1- and 2-year survival, QOL, and immune-related indices (CD4+, CD4+/CD8+), indicating that EI can enhance the therapeutic effect of PBC and strengthen the body’s immunity, which is conducive to the continuation and smooth implementation of antitumor therapy and prolongs patient survival (163). This evidence concerns the gene CD4 and primary biliary cholangitis.